Stanley Erck, Novavax CEO (Lee Jin-wook/Yonhap via AP Images)

No­vavax says its vac­cine is 80% ef­fec­tive in teens, but man­u­fac­tur­ing ques­tions con­tin­ue to cloud fu­ture

No­vavax fi­nal­ly sub­mit­ted an ap­pli­ca­tion for emer­gency use au­tho­riza­tion for its Covid-19 vac­cine late last month. Now a sec­ond ap­pli­ca­tion may al­ready be in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.